PTC Therapeutics Valuation
| PTCT Stock | USD 56.63 0.35 0.61% |
At this time, the company appears to be undervalued. PTC Therapeutics owns a latest Real Value of $61.74 per share. The recent price of the company is $56.63. Our model determines the value of PTC Therapeutics from examining the company fundamentals such as operating margin of (0.07) %, and Return On Asset of -0.0509 as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting PTC Therapeutics' valuation include:
Price Book 1.7 K | Enterprise Value | Enterprise Value Ebitda (10.22) | Price Sales 5.5703 | Forward PE 20.7469 |
Undervalued
Today
Please note that PTC Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of PTC Therapeutics is based on 3 months time horizon. Increasing PTC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
PTC Therapeutics' intrinsic value may or may not be the same as its current market price of 56.63, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 56.63 | Real 61.74 | Target 58.36 | Hype 55.67 | Naive 59.26 |
The intrinsic value of PTC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PTC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PTC Therapeutics helps investors to forecast how PTC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PTC Therapeutics more accurately as focusing exclusively on PTC Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use PTC Therapeutics' intrinsic value based on its ongoing forecasts of PTC Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against PTC Therapeutics' closest peers.
PTC Therapeutics Cash |
|
PTC Valuation Trend
PTC Therapeutics' real value is important for investors to make better decisions and a more accurate overall view of PTC Therapeutics' financial worth over time. Using both PTC Therapeutics' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
PTC Revenue by Product
PTC Therapeutics Total Value Analysis
PTC Therapeutics is at this time forecasted to have valuation of 5.71 B with market capitalization of 4.49 B, debt of 389.3 M, and cash on hands of 288.43 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the PTC Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.71 B | 4.49 B | 389.3 M | 288.43 M |
PTC Therapeutics Investor Information
About 100.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.81. PTC Therapeutics recorded a loss per share of 4.73. The entity had not issued any dividends in recent years. Based on the key indicators related to PTC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PTC Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.PTC Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PTC Therapeutics has an asset utilization ratio of 47.32 percent. This implies that the Company is making $0.47 for each dollar of assets. An increasing asset utilization means that PTC Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.PTC Therapeutics Ownership Allocation
PTC Therapeutics secures a total of 78.87 Million outstanding shares. The majority of PTC Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to secure positions in PTC Therapeutics to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in PTC Therapeutics. Please pay attention to any change in the institutional holdings of PTC Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that around one million seven hundred ninety-eight thousand two hundred twenty-two invesors are currently shorting PTC Therapeutics expressing very little confidence in its future performance.PTC Therapeutics Profitability Analysis
The company reported the previous year's revenue of 806.78 M. Net Loss for the year was (363.3 M) with profit before overhead, payroll, taxes, and interest of 214.9 M.About PTC Therapeutics Valuation
The stock valuation mechanism determines PTC Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of PTC Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of PTC Therapeutics. We calculate exposure to PTC Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PTC Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 806.8 M | 847.1 M | |
| Pretax Profit Margin | (0.45) | (0.47) | |
| Operating Profit Margin | (0.38) | (0.39) | |
| Net Loss | (0.45) | (0.47) | |
| Gross Profit Margin | 0.84 | 0.88 |
PTC Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as PTC Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 76.8 M | |
| Forward Price Earnings | 20.7469 |
PTC Therapeutics Current Valuation Indicators
PTC Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final PTC Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as PTC Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use PTC Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes PTC Therapeutics' worth.Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.